Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.